Back

Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells

Paulsohn, M.-B.; Frahnert, K. H.; Fang, X.; Schneider, C.; Tapia Contreras, C.; Schneider, G.; Hessmann, E.; Dobbelstein, M.

2025-01-14 cancer biology
10.1101/2025.01.11.632518 bioRxiv
Show abstract

Mutant Ras oncoproteins, particularly KRAS, are among the most prevalent drivers of cancer. Small-molecule inhibitors of KRAS have been developed, bearing high potential for cancer therapy but considerable risk of resistance development. To avoid cancer cell adaptation, effective combinatorial partners for increasing immediate efficacy remain to be explored. Here, we demonstrate that combining the KRAS inhibitor Sotorasib with the CDK4/6 inhibitor Palbociclib synergistically eliminates pancreatic ductal adenocarcinoma (PDAC) cells and organoids harboring KRAS G12C mutations. This synergy was particularly pronounced after drug washout, indicating a durable impact. Similar effects were observed in non-small-cell lung cancer (NSCLC) cells. Additionally, MRTX1133, a KRAS G12D inhibitor, synergized with Palbociclib to suppress KRAS G12D-mutant PDAC-derived cells. Mechanistically, these combinations induced sustained cell cycle arrest through reduced RB phosphorylation, decreased E2F1 levels, and increased CDKN1B/p27 expression. Deletion of CDKN1B largely rescued tumor cell proliferation, underscoring its critical role in mediating the observed synergy. These findings support the therapeutic potential of combining KRAS and CDK4/6 inhibitors for treating PDAC and other Ras-driven cancers.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.1%
18.3%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 2%
9.6%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 21%
7.8%
Similar papers in this journal
4
Cancer Research
● 130 papers in training set
Top 0.3%
7.8%
Similar papers in this journal
5
Oncogene
○ 85 papers in training set
Top 0.3%
6.2%
Similar papers in this journal
6
eLife
● 5828 papers in training set
Top 22%
5.5%
50% of probability mass above
7
Cancer Discovery
● 66 papers in training set
Top 0.5%
5.1%
8
Cancer Cell
○ 42 papers in training set
Top 0.3%
3.5%
9
Molecular Oncology
○ 55 papers in training set
Top 0.3%
3.2%
10
Cell Reports Medicine
○ 153 papers in training set
Top 2%
2.1%
11
Nature Cancer
○ 39 papers in training set
Top 0.8%
1.9%
12
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.5%
1.7%
13
Science Advances
● 1243 papers in training set
Top 22%
1.5%
14
Journal of Experimental Medicine
● 119 papers in training set
Top 2%
1.3%
15
Science Signaling
● 65 papers in training set
Top 1.0%
1.1%
16
British Journal of Cancer
○ 49 papers in training set
Top 1%
1.1%
17
Cell Chemical Biology
○ 94 papers in training set
Top 1%
1.1%
18
Gastroenterology
○ 42 papers in training set
Top 0.8%
1.1%
19
The EMBO Journal
○ 309 papers in training set
Top 5%
1.0%
20
Molecular Cancer
○ 16 papers in training set
Top 0.3%
1.0%
21
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 39%
1.0%
22
iScience
○ 1154 papers in training set
Top 37%
0.8%
23
Journal of Clinical Investigation
● 179 papers in training set
Top 6%
0.8%
24
Molecular Systems Biology
○ 162 papers in training set
Top 3%
0.8%
25
Genome Medicine
○ 183 papers in training set
Top 5%
0.8%
26
Life Science Alliance
● 285 papers in training set
Top 10%
0.6%
27
Cancer Letters
○ 35 papers in training set
Top 1%
0.6%
28
Communications Biology
○ 993 papers in training set
Top 36%
0.6%
29
EMBO Reports
○ 263 papers in training set
Top 8%
0.6%
30
Clinical Cancer Research
● 64 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.